MedTrace Logo

Novel GPC3 CAR-T Cell Therapy for Hepatocellular Carcinoma

NCT05344664 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2022-04-25

No results posted yet for this study

Summary

This is a single-center, single-arm, open-label Phase I study to evaluate the safety and efficacy of GPC3-CAR-T cell immunotherapy in the treatment of hepatocellular carcinoma.

Interventions

BIOLOGICAL

GPC3-CAR-T cells

The patients will receive one dose of GPC3-CAR-T.The dosage ranges from3×10\^6 to 1×10\^8 CAR-T+/kg.

Sponsors & Collaborators

  • Peking University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-14
Primary Completion
2024-10-14
Completion
2025-02-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05344664 on ClinicalTrials.gov